Trials / Completed
CompletedNCT04100096
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | Tablet |
| OTHER | Placebo | Tablet |
Timeline
- Start date
- 2019-10-17
- Primary completion
- 2021-06-27
- Completion
- 2021-06-27
- First posted
- 2019-09-24
- Last updated
- 2024-07-18
- Results posted
- 2024-07-18
Locations
77 sites across 3 countries: United States, Spain, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04100096. Inclusion in this directory is not an endorsement.